Bellevue Group AG Boosts Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Bellevue Group AG increased its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 1.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 753,621 shares of the company’s stock after buying an additional 11,766 shares during the quarter. Bellevue Group AG’s holdings in Health Catalyst were worth $41,834,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HCAT. BlackRock Inc. increased its holdings in Health Catalyst by 78.8% during the second quarter. BlackRock Inc. now owns 4,519,656 shares of the company’s stock worth $250,888,000 after buying an additional 1,991,894 shares during the last quarter. Perceptive Advisors LLC increased its holdings in Health Catalyst by 83.3% during the first quarter. Perceptive Advisors LLC now owns 506,084 shares of the company’s stock worth $23,670,000 after buying an additional 230,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Health Catalyst by 490.4% during the first quarter. Dimensional Fund Advisors LP now owns 225,875 shares of the company’s stock worth $10,564,000 after buying an additional 187,617 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Health Catalyst during the first quarter worth about $7,365,000. Finally, Alliancebernstein L.P. increased its holdings in Health Catalyst by 7.5% during the second quarter. Alliancebernstein L.P. now owns 2,124,875 shares of the company’s stock worth $117,952,000 after buying an additional 147,927 shares during the last quarter.

HCAT has been the subject of several recent research reports. Citigroup lifted their target price on shares of Health Catalyst from $62.00 to $68.00 and gave the stock a “buy” rating in a research note on Monday, August 9th. Zacks Investment Research upgraded shares of Health Catalyst from a “sell” rating to a “hold” rating in a research note on Tuesday, September 21st. SVB Leerink reiterated a “buy” rating on shares of Health Catalyst in a research note on Sunday. Canaccord Genuity lifted their target price on shares of Health Catalyst from $60.00 to $64.00 and gave the stock a “buy” rating in a research note on Friday, August 6th. Finally, Piper Sandler lifted their target price on shares of Health Catalyst from $57.00 to $66.00 and gave the stock an “overweight” rating in a research note on Friday, August 6th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $60.00.

HCAT stock opened at $53.70 on Monday. The firm has a 50 day moving average of $54.41 and a 200-day moving average of $53.29. Health Catalyst, Inc. has a 12 month low of $31.65 and a 12 month high of $59.50. The firm has a market capitalization of $2.50 billion, a P/E ratio of -17.10 and a beta of 0.63.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Thursday, August 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. Health Catalyst had a negative net margin of 62.31% and a negative return on equity of 24.68%. The business had revenue of $59.63 million during the quarter, compared to analyst estimates of $56.68 million. Analysts anticipate that Health Catalyst, Inc. will post -1.83 EPS for the current fiscal year.

In other Health Catalyst news, General Counsel Daniel H. Orenstein sold 2,500 shares of Health Catalyst stock in a transaction that occurred on Thursday, July 1st. The shares were sold at an average price of $55.98, for a total transaction of $139,950.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Linda Llewelyn sold 3,260 shares of the business’s stock in a transaction that occurred on Thursday, July 1st. The stock was sold at an average price of $55.86, for a total transaction of $182,103.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 149,451 shares of company stock valued at $8,202,064. 2.00% of the stock is currently owned by company insiders.

Health Catalyst Company Profile

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

Featured Story: The limitations of an equal weight rating

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.